-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|October 1, 2001

Supplements and Featured Publications

Cost and Utilization Analysis for Allergic Rhinitis Treatments: A Managed Care Update
Volume 7
Issue 15 Suppl

The Costs of Nonsedating Antihistamine Therapy for Allergic Rhinitis in Managed Care: An Update Analysis

Author(s)Edward Liao, PharmD, Michael Leahy, MBA, Gordon Cummins

Download PDF: The Costs of Nonsedating Antihistamine Therapy for Allergic Rhinitis in Managed Care: An Update Analysis

Articles in this issue

almost 25 years ago

Article

Participating Faculty

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

AJMC Letter to the Editor

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

AJMC original research policy

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

AJMC commentary

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

AJMC commentary

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

AJMC original research policy

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

5 Notable FDA Approvals From the First Half of 2026